Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease

Physiological Reports

Volumn 5, Issue 7, 2017, Pages

  Ma, Qiuyue ^a   Steiger, Stefanie ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Crystal; diabetic nephropathy; glomerulosclerosis; progression

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALCIUM; CALCIUM OXALATE; CALVASCULIN; COLLAGEN TYPE 1; CREATININE; EMPAGLIFLOZIN; FIBRONECTIN; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; OXALIC ACID; SODIUM GLUCOSE COTRANSPORTER 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; BENZHYDRYL DERIVATIVE; GLUCOSIDE; HAVCR1 PROTEIN, MOUSE; PROTECTIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; COLORIMETRY; ENZYMATIC ASSAY; FEEDING; GLOMERULUS FILTRATION RATE; HISTOLOGY; HYPEROXALURIA; KIDNEY CALCIFICATION; KIDNEY FIBROSIS; KIDNEY FUNCTION; MORPHOMETRY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY; METABOLISM;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD UREA NITROGEN; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEPATITIS A VIRUS CELLULAR RECEPTOR 1; KIDNEY; MICE; MICE, INBRED C57BL; OXALIC ACID; PROTECTIVE AGENTS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 85017527761     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13228     Document Type: Article

References (24)

1. Anders, H. J., J. M. Davis, and K. Thurau. 2016. Nephron protection in diabetic kidney disease. N. Engl. J. Med. 24:2096–2098.
2. Asselman, M., A. Verhulst, M. E. De Broe, and C. F. Verkoelen. 2003. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J. Am. Soc. Nephrol. 14:3155–3166.
3. Bilous, R. 2008. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabetes Med. 25(Suppl 2):25–29.
4. Carlstrom, M., C. S. Wilcox, and W. J. Arendshorst. 2015. Renal autoregulation in health and disease. Physiol. Rev. 95:405–511.
5. Cochat, P., and G. Rumsby. 2013. Primary hyperoxaluria. N. Engl. J. Med. 369:649–658.
6. Eckardt, K. U., J. Coresh, O. Devuyst, R. J. Johnson, A. Kottgen, A. S. Levey, et al. 2013. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382:158–169.
7. de Galan, B. E., V. Perkovic, T. Ninomiya, A. Pillai, A. Patel, A. Cass, et al. 2009. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 20:883–892.
8. Gallo, L. A., M. S. Ward, A. K. Fotheringham, A. Zhuang, D. J. Borg, N. B. Flemming, et al. 2016. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci. Rep. 6:26428.
9. Gembardt, F., C. Bartaun, N. Jarzebska, E. Mayoux, V. T. Todorov, B. Hohenstein, et al. 2014. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. Physiol. Renal Physiol. 307:F317–F325.
10. Group, A. S., W. C. Cushman, G. W. Evans, R. P. Byington, D. C. Goff Jr, R. H. Grimm Jr., et al. 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362:1575–1585.
11. Ismail-Beigi, F., T. Craven, M. A. Banerji, J. Basile, J. Calles, R. M. Cohen, et al. 2010. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419–430.
12. Ismail-Beigi, F., T. E. Craven, P. J. O'Connor, D. Karl, J. Calles-Escandon,I. Hramiak, et al. 2012. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 81:586–594.
13. Knauf, F., J. R. Asplin, I. Granja, I. M. Schmidt, G. W. Moeckel, R. J. David, et al. 2013. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 84:895–901.
14. Liakos, A., T. Karagiannis, E. Athanasiadou, M. Sarigianni, M. Mainou, K. Papatheodorou, et al. 2014. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 16:984–993.
15. Mulay, S. R., J. N. Eberhard, J. Desai, J. A. Marschner, S. V. Kumar, M. Weidenbusch, et al. 2016. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am. J. Physiol. Renal Physiol. 310:F785–F795.
16. Mulay, S. R., J. N. Eberhard, V. Pfann, J. A. Marschner, M. N. Darisipudi, C. Daniel, et al. 2016. Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J. Am. Soc. Nephrol. 28:761–768
17. Ojima, A., T. Matsui, Y. Nishino, N. Nakamura, and S. Yamagishi. 2015. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm. Metab. Res. 47:686–692.
18. Remuzzi, G., A. Benigni, and A. Remuzzi. 2006. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116:288–296.
19. Schreiber, A., Y. Shulhevich, S. Geraci, J. Hesser, D. Stsepankou, S. Neudecker, et al. 2012. Transcutaneous measurement of renal function in conscious mice. Am. J. Physiol. Renal Physiol. 303:F783–F788.
20. Skrtic, M., and D. Z. Cherney. 2015. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 24:96–103.
21. UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713.
22. Vallon, V. 2015. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 66:255–270.
23. Wanner, C., S. E. Inzucchi, J. M. Lachin, D. Fitchett, von Eynatten M., M. Mattheus, et al. 2016. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375:1801–1802
24. Zhang, Y., K. Thai, D. M. Kepecs, and R. E. Gilbert. 2016. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS ONE 11:e0144640.